FindTrial
Sign In

Clinical study of Brivaracetam in managing seizures

To assess the safety and effectiveness of Brivaracetam in the management of focal and secondary generalized tonic clonic seizures through an observational, multicenter study - BEAM

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/06/068394
Enrollment
4530
Registered
2024-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset

Interventions

None listed

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Male or female patients with Partial onset seizures 16 years of age and older with epilepsy. 2) Patients diagnosed with epilepsy and treated with brivaracetam sustained release tablets.

Exclusion criteria

Exclusion criteria: Patients allergic to brivaracetam sustained release tablets or any of the ingredients in medicine.

Design outcomes

Primary

MeasureTime frame
Change in Seizure FrequencyTimepoint: 4 weeks—

Secondary

MeasureTime frame
Clinicians Global Impression – Efficacy Index (CGI-EI)Timepoint: 4 weeks;Demographic patternTimepoint: Baseline;Other Anti-epileptic drugs (AEDs) used along with BRV SRTimepoint: Baseline, 4 weeks;Prevalence of other co-morbid conditions along with EpilepsyTimepoint: Baseline;Responders RateTimepoint: 4 weeks;Safety assessments in terms of AEsTimepoint: 4 weeks;Seizure FreedomTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactDr Krishnaprasad K

Department of Neurology, 3rd Floor, Rudra Arcade

dr.harshutishah@proton.me9825074703

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026